Bildkälla: Stockfoto

Biovica Q4 2021/22: The Final Countdown - Redeye

Biovica can point to significant progress lately. The FDA submission was cleared well before schedule, and DiviTum is securing additional scientific support, including the independent BioItaLEE study at ASCO related to Novartis CDK4/6i product.

Biovica can point to significant progress lately. The FDA submission was cleared well before schedule, and DiviTum is securing additional scientific support, including the independent BioItaLEE study at ASCO related to Novartis CDK4/6i product.
Börsvärldens nyhetsbrev
ANNONSER